

Queensland Clinical Guidelines

Translating evidence into best clinical practice

Maternity and Neonatal **Clinical Guideline**

Guideline Supplement: Perinatal mental health

Table of Contents

1	Introduction.....	3
1.1	Funding.....	3
1.2	Conflict of interest.....	3
1.3	Development process.....	3
1.4	Summary of changes.....	3
2	Methodology.....	4
2.1	Topic identification.....	4
2.2	Scope.....	4
2.3	Clinical questions.....	5
2.4	Search strategy.....	6
2.4.1	Keywords.....	6
2.5	Consultation.....	7
2.6	Endorsement.....	7
2.7	Citation.....	7
3	Levels of evidence.....	8
3.1	Summary recommendations.....	9
4	Implementation.....	9
4.1	Guideline resources.....	9
4.2	Suggested resources.....	10
4.3	Implementation measures.....	10
4.3.1	QCG measures.....	10
4.3.2	Hospital and Health Service measures.....	10
4.3.3	Implications for implementation.....	10
4.4	Quality measures.....	11
4.5	Areas for future research.....	11
4.6	Safety and quality.....	12
	References.....	20

List of Tables

Table 1.	Summary of change.....	3
Table 2.	Scope framework.....	4
Table 3.	Basic search strategy.....	6
Table 4.	Major guideline development processes.....	7
Table 5.	Summary recommendations.....	9
Table 6.	NSQHS Standard 1.....	11
Table 7.	Clinical quality measures.....	11
Table 8.	NSQHS.....	12

© State of Queensland (Queensland Health) 2024



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For further information contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au. For permissions beyond the scope of this licence contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au

1 Introduction

This document is a supplement to the Queensland Clinical Guideline (QCG) *Name of Guideline*. It provides supplementary information regarding guideline development, makes summary recommendations, suggests measures to assist implementation and quality activities and summarises changes (if any) to the guideline since original publication. Refer to the guideline for abbreviations, acronyms, flow charts and acknowledgements.

1.1 Funding

The development of this guideline was funded by:

- Mental Health, Alcohol and Other Drugs Strategy and Planning Branch, Queensland Health and the Commonwealth Government via the Bilateral Schedule on Mental Health and Suicide Prevention
- Healthcare Improvement Unit, Queensland Health

1.2 Conflict of interest

Declarations of conflict of interest were sought from working party members as per the Queensland Clinical Guidelines [Conflict of Interest](#) statement. No conflict of interest was identified.

1.3 Development process

This version of the guideline followed the [QCG New development process](#).

1.4 Summary of changes

Queensland clinical guidelines are reviewed every 5 years or earlier if significant new evidence emerges. Table 1 provides a summary of changes made to the guidelines since original publication.

Table 1. Summary of change

Publication date <i>Endorsed by:</i>	Identifier	Summary of major change
April 2024 <i>Queensland Maternity and Neonatal Clinical Network</i>	MN24.76-V1-29	First publication

2 Methodology

Queensland Clinical Guidelines (QCG) follows a rigorous process of guideline development. This process was endorsed by the Queensland Health Patient Safety and Quality Executive Committee in December 2009. The guidelines are best described as 'evidence informed consensus guidelines' and draw from the literature, the evidence base of existing national and international guidelines and the expert opinion of the working party.

2.1 Topic identification

The topic was identified as a priority by the Bilateral Schedule on Mental Health and Suicide Prevention in 2022, and the Queensland Maternity and Perinatal Quality Council in 2019 and 2021.

2.2 Scope

The scope of the guideline was determined using the following framework.

Table 2. Scope framework

Scope framework	
Population	Women, infants and partners from pre-conception to two years after birth (perinatal period)
Purpose	<p>Identify relevant evidence related to:</p> <ul style="list-style-type: none"> • Pre-conception care for women with history of, or current mental health conditions or concerns • Supporting mental health and emotional wellbeing throughout the perinatal period • Screening and assessment during the perinatal period for: <ul style="list-style-type: none"> ○ Depression and anxiety ○ Current and previous mental health conditions ○ Symptoms of mental illness (including early signs and subclinical symptoms) ○ Mental health consequences related to adverse childhood events and previous trauma • Impact of mental health conditions on pregnancy, fetal wellbeing, infant wellbeing and infant development • Principles of perinatal care for women with mental health conditions • Assessment and management of infant mental health in the first two years of life
Outcome	<ul style="list-style-type: none"> • Evidence informed pre-conception care for women with history of, or current mental health conditions • Timely identification of women with mental health conditions across the perinatal period • Support of evidence informed preparation for pregnancy, birth and parenthood • Timely identification of deteriorating mental health in the perinatal period with appropriate referral and escalation of care • Optimised infant mental health during the perinatal period through timely assessment and appropriate management of identified concerns
Exclusions	<ul style="list-style-type: none"> • Detailed and specific guidance about the diagnosis and management of mental health conditions in perinatal period • Screening, assessment and care specific to: <ul style="list-style-type: none"> ○ Smoking and substance use ○ Domestic and family violence ○ Pregnancy loss (e.g. termination of pregnancy, early pregnancy loss, stillbirth) • Routine antenatal, intrapartum and postpartum care • Infant/child mental health beyond two years postpartum • Care specific to other Queensland Clinical Guidelines including: <ul style="list-style-type: none"> ○ <i>Standard care</i>¹ ○ <i>Perinatal substance use: maternal</i>² and <i>neonatal</i>³ ○ <i>Stillbirth care</i>⁴ ○ <i>Early pregnancy loss</i>⁵ ○ <i>Termination of pregnancy</i>⁶

2.3 Clinical questions

The following clinical questions were generated to inform the guideline scope and purpose:

- What preconception care is recommended for women with history of, or current mental health conditions?
- What mental health conditions may occur during the perinatal period?
- How can mental health and emotional wellbeing of women and partners be supported during the perinatal period?
- How are mental health conditions screened for and identified during the perinatal period?
- What are the referral and care pathways for women (and partners) with mental health concerns?
- What are the principles of care that are recommended for women (and partners) with a perinatal mental health condition?
- How can infant mental health be optimised in the first two years of life?

2.4 Search strategy

A search of the literature was conducted during January 2023–April 2023. A further search was conducted in September 2023. The QCG search strategy is an iterative process that is repeated and amended as guideline development occurs (e.g. if additional areas of interest emerge, areas of contention requiring more extensive review are identified or new evidence is identified). All guidelines are developed using a basic search strategy. This involves both a formal and informal approach.

Table 3. Basic search strategy

Step		Consideration
1.	Review clinical guidelines developed by other reputable groups relevant to the clinical speciality	<ul style="list-style-type: none"> • This may include national and/or international guideline writers, professional organisations, government organisations, state based groups. • This assists the guideline writer to identify: <ul style="list-style-type: none"> ○ The scope and breadth of what others have found useful for clinicians and informs the scope and clinical question development ○ Identify resources commonly found in guidelines such as flowcharts, audit criteria and levels of evidence ○ Identify common search and key terms ○ Identify common and key references
2.	Undertake a foundation search using key search terms	<ul style="list-style-type: none"> • Construct a search using common search and key terms identified during Step 1 above • Search the following databases <ul style="list-style-type: none"> ○ PubMed ○ CINAHL ○ Medline ○ Cochrane Central Register of Controlled Trials ○ EBSCO ○ Embase • Studies published in English less than or equal to 5 years previous are reviewed in the first instance. Other years may be searched as are relevant to the topic • Save and document the search • Add other databases as relevant to the clinical area
3.	Develop search word list for each clinical question	<ul style="list-style-type: none"> • This may require the development of clinical sub-questions beyond those identified in the initial scope. • Using the foundation search performed at Step 2 as the baseline search framework, refine the search using the specific terms developed for the clinical question • Save and document the search strategy undertaken for each clinical question
4.	Other search strategies	<ul style="list-style-type: none"> • Search the reference lists of reports and articles for additional studies • Access other sources for relevant literature <ul style="list-style-type: none"> ○ Known resource sites ○ Internet search engines ○ Relevant textbooks

2.4.1 Keywords

The following keywords were used in the basic search strategy: perinatal mental health, perinatal/antenatal/postnatal depression, perinatal/antenatal/postnatal psychosis, screening, assessment, infant mental health, post-traumatic stress, birth trauma, bipolar, eating disorder. Other keywords may have been used for specific aspects of the guideline.

2.5 Consultation

Major consultative and development processes occurred between July 2023 and January 2024.

Table 4. Major guideline development processes

Process	Activity
Clinical lead	<ul style="list-style-type: none"> The nominated clinical leads were approved by QCG Steering Committee
Consumer participation	<ul style="list-style-type: none"> Consumer participation was invited from a range of consumers. Four consumer representatives were accepted onto the working party and feedback was received from additional consumers during statewide consultation.
Working party	<ul style="list-style-type: none"> An EOI for working party membership was distributed via email to Queensland clinicians and stakeholders in March 2023 The working party was recruited from responses received Working party members who participated in the working party consultation processes are acknowledged in the guideline Working party consultation occurred in a virtual group via email
Statewide consultation	<ul style="list-style-type: none"> Consultation was invited from Queensland clinicians and stakeholders during October 2023–November 2023 Feedback was received primarily via email All feedback was compiled and provided to the clinical lead and working party members for review and comment

2.6 Endorsement

The guideline was endorsed by the:

- Queensland Clinical Guidelines Steering Committee in March 2024
- Queensland Maternity and Neonatal Clinical Network in April 2024

2.7 Citation

The recommended citation of Queensland Clinical Guidelines is in the following format:

Queensland Clinical Guidelines. **[Insert Guideline Title]**. Guideline No. **[Insert Guideline Number]**. Queensland Health. **[Insert Year of Publication]**. Available from: www.health.qld.gov.au/qcg.

EXAMPLE:

Queensland Clinical Guidelines. Normal birth. Guideline No. MN17.25-V3-R22. Queensland Health 2017. Available from: www.health.qld.gov.au/qcg.

3 Levels of evidence

Formal grading of levels of evidence and strength of recommendations were adopted from the Australian Clinical Practice Guideline: Mental health care in the perinatal period (2023 revision).⁷

Types of guidance include:

- **Evidence-based recommendations (EBR):** a recommendation formulated after a systematic review of the evidence, with a clear linkage from the evidence base to the recommendation using GRADE methods and graded either:
 - **Strong:** implies that most/all individuals will be best served by the recommended course of action; used when confident that desirable effects clearly outweigh undesirable effects, or conversely, when confident that undesirable effects clearly outweigh desirable effects.
 - **Conditional:** implies that not all individuals will be best served by the recommended course of action; used when desirable effects probably outweigh undesirable effects; used when undesirable effects probably outweigh desirable effects.
- **Consensus-based recommendations (CBR):** a recommendation formulated in the absence of quality evidence, after a systematic review of the evidence was conducted and failed to identify sufficient admissible evidence on the clinical question.
- **Practice point (PP):** advice on a subject that is outside the scope of the search strategy for the systematic evidence review, based on expert opinion and formulated by a consensus process.

3.1 Summary recommendations

Summary recommendations and levels of evidence are outlined in Table 5. Summary recommendations.

Table 5. Summary recommendations

Recommendations		Strength of recommendation
1.	Administer the Edinburgh Postnatal Depression Scale (EPDS) to screen women for a possible depressive disorder in the perinatal period.	EBR—Strong
2.	Arrange further assessment of perinatal women with an EPDS score of 13 or more.	EBR—Strong
3.	For a woman with a positive score on Question 10 on the EPDS undertake or arrange immediate further mental health assessment and, if there is any disclosure of suicidal ideation, take urgent action in accordance with local protocol/policy.	CBR
4.	Complete the first antenatal screening as early as practical in pregnancy and repeat screening at least once later in pregnancy.	CBR
5.	Complete the first postnatal screening 6–12 weeks after birth and repeat screening at least once in the first postnatal year.	CBR
6.	For a woman with an EPDS score between 10 and 12, monitor and repeat the EPDS in 2–4 weeks as her score may change subsequently. Use clinical judgment in monitoring and further care.	CBR
7.	Repeat the EPDS at any time in pregnancy and in the first postnatal year if indicated.	CBR
8.	When screening Aboriginal and/or Torres Strait Islander women, consider language and cultural appropriateness of the tool.	CBR
9.	Be aware that anxiety disorders are very common in the perinatal period and should be considered in the broader clinical assessment.	CBR
10.	As part of the clinical assessment, use anxiety items from the EPDS or other validated tools that include anxiety items in structured psychosocial assessment tools (e.g. Antenatal Risk Questionnaire (ANRQ))	CBR
11.	Administer the ANRQ to assess a woman's psychosocial risk.	EBR—Strong
12.	Assess psychosocial risk factors as early as practical in pregnancy and again after the birth.	PP
13.	At every antenatal or postnatal visit, enquire about a woman's emotional and physical wellbeing, and the wellbeing of her partner if appropriate.	PP
14.	Provide all women with information about the importance of enquiring about, and attending to, any mental health problems that might arise across the perinatal period.	CBR
15.	Discuss the potential risks and benefits of pharmacological treatment in each individual case with the woman and, where possible, her significant other(s). Document the discussion.	PP

4 Implementation

This guideline is applicable to all Queensland public and private maternity facilities. It can be downloaded in Portable Document Format (PDF) from www.health.qld.gov.au/qcg

4.1 Guideline resources

The following guideline components are provided on the website as separate resources:

- Flowchart: Screening recommendations for women in the perinatal period
- Education resource: Perinatal mental health
- Knowledge assessment: Perinatal mental health
- Parent information: Perinatal mental health

4.2 Suggested resources

During the development process stakeholders identified additional resources with potential to complement and enhance guideline implementation and application. The following resources have not been sourced or developed by QCG but are suggested as complimentary to the guideline:

- Local referral pathways for:
 - Locally available resources and services
 - Queensland and Australia wide resources
- Local safety plan template
- Suicide risk assessment framework for the perinatal period
- Education, support and training for perinatal mental health screening tools and platforms
- Education resources for eating disorders in the perinatal period
- Education and training for trauma informed care in the perinatal period

4.3 Implementation measures

Suggested activities to assist implementation of the guideline are outlined below.

4.3.1 QCG measures

- Notify Chief Executive Officer and relevant stakeholders
- Monitor emerging new evidence to ensure guideline reflects contemporaneous practice
- Capture user feedback
- Record and manage change requests

4.3.2 Hospital and Health Service measures

Initiate, promote and support local systems and processes to integrate the guideline into clinical practice, including:

- Hospital and Health Service (HHS) Executive endorse the guidelines and their use in the HHS and communicate this to staff
- Promote the introduction of the guideline to relevant health care professionals
- Support education and training opportunities relevant to the guideline and service capabilities
- Align clinical care with guideline recommendations
- Undertake relevant implementation activities as outlined in the *Guideline implementation checklist* available at www.health.qld.gov.au/qcg

4.3.3 Implications for implementation

The following areas may have implications for local implementation of the guideline recommendations. It is suggested they be considered for successful guideline implementation.

- Economic considerations including opportunity costs
- Human resource requirements including clinician skill mix and scope of practice
- Clinician education and training
- Equipment and consumables purchase and maintenance
- Consumer acceptance
- Model of care and service delivery

4.4 Quality measures

Auditing of guideline recommendations and content assists with identifying quality of care issues and provides evidence of compliance with the National Safety and Quality Health Service (NSQHS) Standards⁸ [Refer to Table 6. NSQHS Standard 1]. Suggested audit and quality measures are identified in Table 7. Clinical quality measures.

Table 6. NSQHS Standard 1

NSQHS Standard 1: Clinical governance	
Clinical performance and effectiveness	
Criterion 1.27:	Actions required:
Evidence based care	a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice
	b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care

The following clinical quality measures are suggested:

Table 7. Clinical quality measures

No	Audit criteria	Guideline section
1.	Proportion of clinicians working in perinatal setting trained in use of screening tools such as EPDS	Section 2.2
2.	Proportion of women screened twice during pregnancy using the EPDS	Section 8.2
3.	Proportion of pregnant women who had the ANRQ administered	Section 5.3
4.	Proportion of postnatal women screened using the EPDS at 6–12 weeks after birth and who had repeat screening at least once in the first year after birth	Section 8.2
5.	For women with: <ul style="list-style-type: none"> • A positive score on Question 10 of EPDS, proportion who had documentation of discussion regarding further assessment and plan for ongoing assessment • An EPDS score of 13 or more, the proportion who had further assessment arranged in accordance with local area policy • An EPDS score between 10 and 12, the proportion of women who had EPDS repeated 2–4 weeks later 	Section 8.2 and 9.2
6.	For women identified as at risk of suicide, proportion who received urgent mental health assessment and treatment	Section 8.2, 9.1 and 9.2
7.	Proportion of antenatal visits where the woman's emotional wellbeing was enquired about	Section 5.1
8.	Proportion of women with depressive symptoms in perinatal period who were advised of potential benefits of peer support groups	Section 2.4

4.5 Areas for future research

During development the following areas were identified as having limited or poor quality evidence to inform clinical decision making. Further research in these areas may be useful.

- Culturally appropriate screening tools for First Nations peoples in Queensland
- Neurodiversity across the perinatal period
- Screening tools for eating disorders in the perinatal period

4.6 Safety and quality

In conjunction with the Queensland Clinical Guideline *Standard care*¹, implementation of this guideline provides evidence of compliance with the National Safety and Quality Health Service Standards⁸.

Table 8. NSQHS

NSQHS Criteria	Actions required	☑ Evidence of compliance
NSQHS Standard 1: Clinical governance		
<p>Patient safety and quality systems Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.</p>	<p>Diversity and high risk groups 1.15 The health service organisation: a. Identifies the diversity of the consumers using its services b. Identifies groups of patients using its services who are at higher risk of harm c. Incorporates information on the diversity of its consumers and higher-risk groups into the planning and delivery of care</p>	<p>☑ Assessment and care appropriate to the cohort of patients is identified in the guideline ☑ High risk groups are identified in the guideline ☑ The guideline is based on the best available evidence</p>
<p>Clinical performance and effectiveness The workforce has the right qualifications, skills and supervision to provide safe, high-quality health care to patients.</p>	<p>Evidence based care 1.27 The health service organisation has processes that: a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care</p>	<p>☑ Queensland Clinical Guidelines is funded by Queensland Health to develop clinical guidelines relevant to the service line to guide safe patient care across Queensland ☑ The guideline provides evidence-based and best practice recommendations for care ☑ The guideline is endorsed for use in Queensland Health facilities. ☑ A desktop icon is available on every Queensland Health computer desktop to provide quick and easy access to the guideline</p>
	<p>Performance management 1.22 The health service organisation has valid and reliable performance review processes that: a. Require members of the workforce to regularly take part in a review of their performance b. Identify needs for training and development in safety and quality c. Incorporate information on training requirements into the organisation's training system</p>	<p>☑ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet http://www.health.qld.gov.au/gcg</p>

NSQHS Criteria	Actions required	☑ Evidence of compliance
NSQHS Standard 1: Clinical governance		
<p>Patient safety and quality systems Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.</p>	<p>Policies and procedures 1.7 The health service organisation uses a risk management approach to: a. Set out, review, and maintain the currency and effectiveness of, policies, procedures and protocols b. Monitor and take action to improve adherence to policies, procedures and protocols c. Review compliance with legislation, regulation and jurisdictional requirements</p>	<ul style="list-style-type: none"> ☑ QCG has established processes to review and maintain all guidelines and associated resources ☑ Change requests are managed to ensure currency of published guidelines ☑ Implementation tools and checklist are provided to assist with adherence to guidelines ☑ Suggested audit criteria are provided in guideline supplement ☑ The guidelines comply with legislation, regulation and jurisdictional requirements
NSQHS Standard 2: Partnering with Consumers		
<p>Health literacy Health service organisations communicate with consumers in a way that supports effective partnerships.</p>	<p>Communication that supports effective partnerships 2.8 The health service organisation uses communication mechanisms that are tailored to the diversity of the consumers who use its services and, where relevant, the diversity of the local community 2.9 Where information for patients, carers, families and consumers about health and health services is developed internally, the organisation involves consumers in its development and review 2.10 The health service organisation supports clinicians to communicate with patients, carers, families and consumers about health and health care so that: a. Information is provided in a way that meets the needs of patients, carers, families and consumers b. Information provided is easy to understand and use c. The clinical needs of patients are addressed while they are in the health service organisation d. Information needs for ongoing care are provided on discharge</p>	<ul style="list-style-type: none"> ☑ Consumer consultation was sought and obtained during the development of the guideline. Refer to the acknowledgement section of the guideline for details ☑ Consumer information is developed to align with the guideline and included consumer involvement during development and review ☑ The consumer information was developed using plain English and with attention to literacy and ease of reading needs of the consumer
<p>Partnering with consumers in organisational design and governance Consumers are partners in the design and governance of the organisation.</p>	<p>Partnerships in healthcare governance planning, design, measurement and evaluation 2.11 The health service organisation: a. Involves consumers in partnerships in the governance of, and to design, measure and evaluate, health care b. Has processes so that the consumers involved in these partnerships reflect the diversity of consumers who use the service or, where relevant, the diversity of the local community 2.14 The health service organisation works in partnership with consumers to incorporate their views and experiences into training and education for the workforce</p>	<ul style="list-style-type: none"> ☑ Consumers are members of guideline working parties ☑ The guideline is based on the best available evidence ☑ The guidelines and consumer information are endorsed by the QCG and Queensland Statewide Maternity and Neonatal Clinical Network Steering Committees which includes consumer membership

NSQHS Criteria	Actions required	☑ Evidence of compliance
NSQHS Standard 2: Partnering with Consumers		
<p>Partnering with consumers in their own care Patients are partners in their own care to the extent that they choose</p>	<p>Healthcare rights and informed consent 2.4 The health service organisation ensures that its informed consent processes comply with legislation and best practice 2.5 The health service organisation has processes to identify: a. The capacity of a patient to make decisions about their own care b. A substitute decision-maker if a patient does not have the capacity to make decisions for themselves</p> <p>Shared decisions and planning care 2.6 The health service organisation has processes for clinicians to partner with patients and/or their substitute decision-maker to plan, communicate, set goals, and make decisions about their current and future care 2.7 The health service organisation supports the workforce to form partnerships with patients and carers so that patients can be actively involved in their own care</p>	<p>☑ This guideline and consumer information provides information for consumers to make informed decisions ☑ This guideline promotes informed consent</p> <p>☑ Consumer information is available for this guideline ☑ Consumers are members of guideline working parties</p>
NSQHS Standard 3: Infection prevention and control systems		
<p>Clinical governance and quality improvement to prevent and control healthcare-associated infections, and support antimicrobial stewardship Systems are in place to support and promote prevention and control of healthcare-associated infections, and improve antimicrobial stewardship.</p>	<p>Integrating clinical governance 3.1 The workforce uses the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for healthcare-associated infections and antimicrobial stewardship b. Managing risks associated with healthcare-associated infections and antimicrobial stewardship</p>	<p>☑ The guideline provides evidence-based and best practice recommendations for care ☑ Recommendations for use of antimicrobials are evidence based</p>
<p>Infection prevention and control systems Patients presenting with, or with risk factors for, infection or colonisation with an organism of local, national or global significance are identified promptly, and receive the necessary management and treatment.</p>	<p>Standard and transmission-based precautions 3.6 Clinicians assess infection risks and use transmission-based precautions based on the risk of transmission of infectious agents, and consider: a. Patients' risks, which are evaluated at referral, on admission or on presentation for care, and re-evaluated when clinically required during care</p>	<p>☑ The guideline provides evidence-based and best practice recommendations for care ☑ Assessment and care appropriate to the cohort of patients is identified in the guideline ☑ High risk groups are identified in the guideline if applicable</p>
<p>Antimicrobial stewardship Systems are implemented for safe and appropriate prescribing and use of antimicrobials as part of an antimicrobial stewardship program</p>	<p>Antimicrobial stewardship 3.15 The health service organisation has an antimicrobial stewardship program that: a. Includes an antimicrobial stewardship policy b. Provides access to, and promotes the use of, current evidence-based Australian therapeutic guidelines and resources on antimicrobial prescribing</p>	<p>☑ The guideline provides evidence-based and best practice recommendations for care ☑ Recommendations for use of antimicrobials are evidence based ☑ If applicable, Australian therapeutic guidelines and resources were used to develop guideline recommendations</p>

NSQHS Criteria	Actions required	<input checked="" type="checkbox"/> Evidence of compliance
NSQHS Standard 4: Medication safety		
<p>Clinical governance and quality improvement to support medication management Organisation-wide systems are used to support and promote safety for procuring, supplying, storing, compounding, manufacturing, prescribing, dispensing, administering and monitoring the effects of medicines</p>	<p>Integrating clinical governance 4.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for medication management b. Managing risks associated with medication management c. Identifying training requirements for medication management</p>	<p><input checked="" type="checkbox"/> The guideline provides current evidence based recommendations about medication</p>
NSQHS Standard 5: Comprehensive care		
<p>Clinical governance and quality improvement to support comprehensive care Systems are in place to support clinicians to deliver comprehensive care</p>	<p>Integrating clinical governance 5.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for comprehensive care b. Managing risks associated with comprehensive care c. Identifying training requirements to deliver comprehensive care Partnering with consumers 5.3 Clinicians use organisational processes from the Partnering with Consumers Standard when providing comprehensive care to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making</p>	<p><input checked="" type="checkbox"/> The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet http://www.health.qld.gov.au/qcg</p> <p><input checked="" type="checkbox"/> The guideline provides evidence-based and best practice recommendations for care</p> <p><input checked="" type="checkbox"/> Consumer information is developed for the guideline</p>

NSQHS Criteria	Actions required	<input checked="" type="checkbox"/> Evidence of compliance
NSQHS Standard 6: Communicating for safety		
<p>Clinical governance and quality improvement to support effective communication Systems are in place for effective and coordinated communication that supports the delivery of continuous and safe care for patients.</p>	<p>Integrating clinical governance 6.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures to support effective clinical communication b. Managing risks associated with clinical communication c. Identifying training requirements for effective and coordinated clinical communication</p> <p>Partnering with consumers 6.3 Clinicians use organisational processes from the Partnering with Consumers Standard to effectively communicate with patients, carers and families during high-risk situations to: a. Actively involve patients in their own care b. Meet the patient’s information needs c. Share decision-making</p> <p>Organisational processes to support effective communication 6.4 The health service organisation has clinical communications processes to support effective communication when: a. Identification and procedure matching should occur b. All or part of a patient’s care is transferred within the organisation, between multidisciplinary teams, between clinicians or between organisations; and on discharge c. Critical information about a patient’s care, including information on risks, emerges or changes</p>	<p><input checked="" type="checkbox"/> Requirements for effective clinical communication by clinicians are identified</p> <p><input checked="" type="checkbox"/> The guideline provides evidence-based and best practice recommendations for communication between clinicians</p> <p><input checked="" type="checkbox"/> The guideline provides evidence-based and best practice recommendations for communication with patients, carers and families</p> <p><input checked="" type="checkbox"/> The guideline provides evidence-based and best practice recommendations for discharge planning and follow –up care</p>
<p>Communication of critical information Systems to effectively communicate critical information and risks when they emerge or change are used to ensure safe patient care.</p>	<p>Communicating critical information 6.9 Clinicians and multidisciplinary teams use clinical communication processes to effectively communicate critical information, alerts and risks, in a timely way, when they emerge or change to: a. Clinicians who can make decisions about care b. Patients, carers and families, in accordance with the wishes of the patient</p> <p>6.10 The health service organisation ensures that there are communication processes for patients, carers and families to directly communicate critical information and risks about care to clinicians</p>	<p><input checked="" type="checkbox"/> Requirements for effective clinical communication of critical information are identified</p> <p><input checked="" type="checkbox"/> Requirements for escalation of care are identified</p>

NSQHS Criteria	Actions required	<input checked="" type="checkbox"/> Evidence of compliance
NSQHS Standard 6: Communicating for safety (continued)		
<p>Correct identification and procedure matching Systems to maintain the identity of the patient are used to ensure that the patient receives the care intended for them.</p>	<p>Correct identification and procedure matching 6.5 The health service organisation: a. Defines approved identifiers for patients according to best-practice guidelines b. Requires at least three approved identifiers on registration and admission; when care, medication, therapy and other services are provided; and when clinical handover, transfer or discharge documentation is generated</p>	<p><input checked="" type="checkbox"/> Requirements for safe and for correct patient identification are identified</p>
<p>Communicating at clinical handover Processes for structured clinical handover are used to effectively communicate about the health care of patients.</p>	<p>Clinical handover 6.7 The health service organisation, in collaboration with clinicians, defines the: a. Minimum information content to be communicated at clinical handover, based on best-practice guidelines b. Risks relevant to the service context and the particular needs of patients, carers and families c. Clinicians who are involved in the clinical handover 6.8 Clinicians use structured clinical handover processes that include: a. Preparing and scheduling clinical handover b. Having the relevant information at clinical handover c. Organising relevant clinicians and others to participate in clinical handover d. Being aware of the patient's goals and preferences e. Supporting patients, carers and families to be involved in clinical handover, in accordance with the wishes of the patient f. Ensuring that clinical handover results in the transfer of responsibility and accountability for care</p>	<p><input checked="" type="checkbox"/> The guideline acknowledges the need for local protocols to support transfer of information, professional responsibility and accountability for some or all aspects of care</p>

NSQHS Criteria	Actions required	<input checked="" type="checkbox"/> Evidence of compliance
NSQHS Standard 7: Blood management		
<p>Clinical governance and quality improvement to support blood management Organisation-wide governance and quality improvement systems are used to ensure safe and high-quality care of patients' own blood, and to ensure that blood product requirements are met.</p>	<p>Integrating clinical governance 7.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for blood management b. Managing risks associated with blood management c. Identifying training requirements for blood management</p>	<p><input checked="" type="checkbox"/> The guideline provides evidence-based and best practice recommendations for use of blood products</p>
<p>Prescribing and clinical use of blood and blood products The clinical use of blood and blood products is appropriate, and strategies are used to reduce the risks associated with transfusion.</p>	<p>Optimising and conserving patients' own blood 7.4 Clinicians use the blood and blood products processes to manage the need for, and minimise the inappropriate use of, blood and blood products by: a. Optimising patients' own red cell mass, haemoglobin and iron stores b. Identifying and managing patients with, or at risk of, bleeding c. Determining the clinical need for blood and blood products, and related risks Prescribing and administering blood and blood products 7.6 The health service organisation supports clinicians to prescribe and administer blood and blood products appropriately, in accordance with national guidelines and national criteria</p>	<p><input checked="" type="checkbox"/> The guideline provides evidence-based and best practice recommendations for use of blood products <input checked="" type="checkbox"/> The guideline is consistent with recommendations of national guidelines</p>

NSQHS Criteria	Actions required	<input checked="" type="checkbox"/> Evidence of compliance
NSQHS Standard 8: Recognising and responding to acute deterioration		
<p>Clinical governance and quality improvement to support recognition and response systems Organisation-wide systems are used to support and promote detection and recognition of acute deterioration, and the response to patients whose condition acutely deteriorates.</p>	<p>Integrating clinical governance 8.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for recognising and responding to acute deterioration b. Managing risks associated with recognising and responding to acute deterioration c. Identifying training requirements for recognising and responding to acute deterioration</p> <p>Partnering with consumers 8.3 Clinicians use organisational processes from the Partnering with Consumers Standard when recognising and responding to acute deterioration to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making</p> <p>Recognising acute deterioration 8.4 The health service organisation has processes for clinicians to detect acute physiological deterioration that require clinicians to: a. Document individualised vital sign monitoring plans b. Monitor patients as required by their individualised monitoring plan c. Graphically document and track changes in agreed observations to detect acute deterioration over time, as appropriate for the patient</p>	<p><input checked="" type="checkbox"/> The guideline is consistent with National Consensus statements recommendations <input checked="" type="checkbox"/> The guideline recommends use of tools consistent with the principles of recognising and responding to clinical deterioration <input checked="" type="checkbox"/> Consumer information is developed for the guideline</p>

References

1. Queensland Clinical Guidelines. Standard care. Guideline No. MN22.50-V2-R27. [Internet]. Queensland Health. 2022. [cited 2024 March 5]. Available from: <https://www.health.qld.gov.au/qcg>.
2. Queensland Clinical Guidelines. Perinatal substance use: maternal Guideline No. MN21.37-V2-R26. [Internet]. Queensland Health. 2021. [cited 2024 February 29]. Available from: <https://www.health.qld.gov.au/qcg>.
3. Queensland Clinical Guidelines. Perinatal substance use: neonatal Guideline No. MN21.38-V3-R26. [Internet]. Queensland Health. 2021. [cited 2024 February 29]. Available from: <https://www.health.qld.gov.au/qcg>.
4. Queensland Clinical Guidelines. Stillbirth care. Guideline No. MN23.24-V10-R28. [Internet]. Queensland Health. 2023. [cited 2024 February 29]. Available from: <https://www.health.qld.gov.au/qcg>.
5. Queensland Clinical Guidelines. Early pregnancy loss. Guideline No. MN22.29-V6-R27. [Internet]. Queensland Health. 2022. [cited 2024 February 29]. Available from: <https://www.health.qld.gov.au/qcg>.
6. Queensland Clinical Guidelines. Termination of pregnancy. Guideline No. MN19.21-V9-R24. [Internet]. Queensland Health. 2019. [cited 2024 February 29]. Available from: <https://www.health.qld.gov.au/qcg>.
7. Hight NJ, and the Expert Working Group and Expert Subcommittees. Mental health care in the perinatal period: Australian clinical practice guideline. [Internet]. 2023 [cited 2023 June 16]. Available from: <https://www.cope.org.au>.
8. Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. [Internet]. 2017 [cited 2024 February 29]. Available from: www.safetyandquality.gov.au.